Draft:Laser focal therapy

United States Prostate Cancer Market and Competitive Landscape Report 2021: Epidemiology, Key Products, Market Valuations and Forecast, Drugs Sales and Market Shares 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 26, 2021
Pharmaceutical, Health, Oncology, Anatomy, Branches of biology, Prostate cancer, Histopathology, Prostate, Epidemiology of cancer, Cancer, Draft:Laser focal therapy

US Prostate Cancer Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Prostate Cancer pipeline products, Prostate Cancer epidemiology, Prostate Cancer market valuations and forecast, Prostate Cancer drugs sales and competitive landscape in the US.

Key Points: 
  • US Prostate Cancer Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Prostate Cancer pipeline products, Prostate Cancer epidemiology, Prostate Cancer market valuations and forecast, Prostate Cancer drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Prostate Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Prostate Cancer drugs: Identify key products marketed and prescribed for Prostate Cancer in the US, including trade name, molecule name, and company
    Prostate Cancer market valuations: Find out the market size for Prostate Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Prostate Cancer drugs market share: Find out the market shares for key Prostate Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Prostate Cancer products

NeoDynamics receives first UK order of pulse biopsy system NeoNavia

Retrieved on: 
Thursday, November 19, 2020
Medicine, Clinical medicine, Medical specialties, Biopsy, Interventional radiology, Breast surgery, Medical equipment, Draft:Laser focal therapy, Renal biopsy

The company has developed an innovative biopsy system, NeoNavia.

Key Points: 
  • The company has developed an innovative biopsy system, NeoNavia.
  • The pulse biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.
  • NeoNavia is the brand name for the entire pulse biopsy system intended to be used under ultrasound guidance.
  • Each needle type is driven by a pulse technology enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion.

NeoDynamics receives first UK order of pulse biopsy system NeoNavia

Retrieved on: 
Thursday, November 19, 2020
Medicine, Clinical medicine, Medical specialties, Biopsy, Interventional radiology, Breast surgery, Medical equipment, Draft:Laser focal therapy, Renal biopsy

The company has developed an innovative biopsy system, NeoNavia.

Key Points: 
  • The company has developed an innovative biopsy system, NeoNavia.
  • The pulse biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.
  • NeoNavia is the brand name for the entire pulse biopsy system intended to be used under ultrasound guidance.
  • Each needle type is driven by a pulse technology enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion.

CLS and Toronto General Hospital Continue Clinical Trial Collaboration Regarding MRI-Guided Laser Ablation Treatment of Prostate Cancer

Retrieved on: 
Tuesday, November 17, 2020
Health, Medicine, Histopathology, Prostate cancer, Interventional radiology, Clinical trial, Magnetic resonance imaging, Cancer, Draft:Laser focal therapy, Management of prostate cancer

The clinical trial started in 2018 to evaluate the safety and efficacy in treating prostate cancer with MRI-guided focal laser ablation (MRgFLA) in 25 patients.

Key Points: 
  • The clinical trial started in 2018 to evaluate the safety and efficacy in treating prostate cancer with MRI-guided focal laser ablation (MRgFLA) in 25 patients.
  • At the time of the presentation, treatment was successfully completed in 21 patients and no adverse events were reported.
  • The conclusion was that MRgFLA shows encouraging short-term oncologic and functional outcomes for the treatment of low-to-intermediate-risk prostate cancer.
  • CLS and Dr. Sangeet Ghai decided to proceed with the collaboration, continue the clinical trial, and extend it to include an additional 30 patients under the same protocol.

CLS and Toronto General Hospital Continue Clinical Trial Collaboration Regarding MRI-Guided Laser Ablation Treatment of Prostate Cancer

Retrieved on: 
Tuesday, November 17, 2020
Health, Medicine, Histopathology, Prostate cancer, Interventional radiology, Clinical trial, Magnetic resonance imaging, Cancer, Draft:Laser focal therapy, Management of prostate cancer

The clinical trial started in 2018 to evaluate the safety and efficacy in treating prostate cancer with MRI-guided focal laser ablation (MRgFLA) in 25 patients.

Key Points: 
  • The clinical trial started in 2018 to evaluate the safety and efficacy in treating prostate cancer with MRI-guided focal laser ablation (MRgFLA) in 25 patients.
  • At the time of the presentation, treatment was successfully completed in 21 patients and no adverse events were reported.
  • The conclusion was that MRgFLA shows encouraging short-term oncologic and functional outcomes for the treatment of low-to-intermediate-risk prostate cancer.
  • CLS and Dr. Sangeet Ghai decided to proceed with the collaboration, continue the clinical trial, and extend it to include an additional 30 patients under the same protocol.

CLS Americas Highlights High-Precision, Image-Guided Laser Ablation System for Prostate Tumors and Soft Tissues at FOCAL2020 Virtual Conference

Retrieved on: 
Tuesday, September 29, 2020
Anatomy, Plasma physics, Medicine, Clinical medicine, Ablation, Prostate cancer, Prostate, Laser ablation, Draft:Laser focal therapy

(CLS Americas), a subsidiary of CLS AB in Lund, Sweden, today announced it will be participating in the upcoming FOCAL2020 Virtual Conference titled, Frontiers in Oncologic Prostate Care and Ablative Local Therapy (Focal) being held this October 3-4, 2020.

Key Points: 
  • (CLS Americas), a subsidiary of CLS AB in Lund, Sweden, today announced it will be participating in the upcoming FOCAL2020 Virtual Conference titled, Frontiers in Oncologic Prostate Care and Ablative Local Therapy (Focal) being held this October 3-4, 2020.
  • The conference offers numerous CME courses available with a broad focus under 3 primary areas: In-Office Transperineal Interventions, Fusion-Guided Prostate Ablation, State-of-the-art BPH Management.
  • CLS is excited to sponsor and participate in the FOCAL2020 virtual conference of panels and workshops covering the latest tissue ablation technologies and treatments for prostate cancer, stated Michael Magnani, managing director of CLS Americas, Inc.
  • CLS developed its TRANBERG Thermal Therapy System with Thermoguide thermometry software and single-use accessories for image-guided, high precision soft tissue thermal therapy and laser ablation of tumors and soft tissues.

2020 U.S. Prostate Cancer Market Analysis and Forecasts

Retrieved on: 
Thursday, August 27, 2020
Anatomy, RTT, Cancer, Branches of biology, Histopathology, Prostate cancer, Prostate, Epidemiology of cancer, Draft:Laser focal therapy, Prostate Cancer Foundation

DUBLIN, Aug. 27, 2020 /PRNewswire/ -- The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 27, 2020 /PRNewswire/ -- The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The "US Prostate Cancer Market and Competitive Landscape Highlights - 2020" report provides comprehensive insights into Prostate Cancer pipeline products, Prostate Cancer epidemiology, Prostate Cancer market valuations and forecast, Prostate Cancer drugs sales and competitive landscape in the US.
  • Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Prostate Cancer drugs: Identify key products marketed and prescribed for Prostate Cancer in the US, including trade name, molecule name, and company
    Prostate Cancer market valuations: Find out the market size for Prostate Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Prostate Cancer drugs market share: Find out the market shares for key Prostate Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Prostate Cancer products

US Prostate Cancer Market and Competitive Landscape 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 24, 2020
Health, Oncology, RTT, Anatomy, Cancer, Branches of biology, Prostate cancer, Histopathology, Prostate, Epidemiology of cancer, Draft:Laser focal therapy, Prostate Cancer Foundation

The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Prostate Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The "US Prostate Cancer Market and Competitive Landscape Highlights - 2020" report provides comprehensive insights into Prostate Cancer pipeline products, Prostate Cancer epidemiology, Prostate Cancer market valuations and forecast, Prostate Cancer drugs sales and competitive landscape in the US.
  • Prostate Cancer pipeline: Find out the products in clinical trials for the treatment of Prostate Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Prostate Cancer drugs: Identify key products marketed and prescribed for Prostate Cancer in the US, including trade name, molecule name, and company
    Prostate Cancer market valuations: Find out the market size for Prostate Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Prostate Cancer drugs market share: Find out the market shares for key Prostate Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Prostate Cancer products

SimonMed Announces the Integration of CorTechs Labs’ Latest AI Software for Prostate Cancer Detection

Retrieved on: 
Wednesday, August 19, 2020
Technology, Medical devices, Software, Practice Management, Hardware, Radiology, General Health, Health, Data management, Oncology, Anatomy, Prostate cancer, Histopathology, RTT, Magnetic resonance imaging, Prostate, Draft:Laser focal therapy, CorTechs Labs, SimonMed

The arrival of RSI-MRI+ for Prostate into the SimonMed network marks an important step in our ability to accurately detect prostate cancer using the latest AI capabilities, said Dr. John Simon, MD, Chief executive officer of SimonMed.

Key Points: 
  • The arrival of RSI-MRI+ for Prostate into the SimonMed network marks an important step in our ability to accurately detect prostate cancer using the latest AI capabilities, said Dr. John Simon, MD, Chief executive officer of SimonMed.
  • I expect RSI-MRI+ to become standard technology across U.S. imaging centers, and transform prostate cancer detection and patient care.
  • RSI-MRI+ for Prostate is FDA-cleared advanced imaging software that supports improved PCa detection for a more accurate diagnosis.
  • This integration of our latest AI software expands the already-extensive deployment of our other AI solutions throughout the SimonMed network of imaging centers, said Chris Airriess, Ph.D., chief executive officer of CorTechs Labs.